Weight Loss Sale

Life Extension Magazine

LE Magazine November 2007
image

Scientific Methods to Reduce Breast and Prostate Cancer Risk


By William Faloon

How Lignans Protect the Breast and Prostate Glands

A number of published studies indicate that dietary lignans may protect against cancer by favorably altering estrogen metabolism, inhibiting angiogenesis, and inducing cancer cells to self destruct.79-81 The greatest support for a role of lignans in cancer prevention has been shown for premenopausal breast cancer.

Researchers in New York assessed breast cancer risk and dietary lignan intake in more than 3,000 women, including about 1,100 patients with confirmed breast cancer and approximately 2,000 cancer-free women who served as controls. Using statistical analysis, the scientists determined that premenopausal women with the highest lignan intake had a 44% reduced risk of developing breast cancer.80

Scientists in Italy reported similar findings. Their research indicates that higher blood levels of enterolactone— the primary lignan derived by the body from flaxseed—are associated with a lower risk of breast cancer. Conversely, the researchers noted, “values of serum enterolactone were significantly lower in women who subsequently developed breast cancer,” leading them to conclude that the phytoestrogen enterolactone “had a strong protective effect on breast cancer risk.”81

Lignans may also protect against endometrial cancer, a condition associated with prolonged exposure to unopposed estrogens. Flax lignans may offer protection through an anti-estrogenic effect in the body. Researchers in California assessed lignan intake and cancer status among nearly 1,000 women in the San Francisco area and determined that women with the highest dietary lignan intake experienced the lowest risk of developing this carcinoma of the uterine lining. The relationship between lignans and endometrial cancer risk reduction was slightly stronger among postmenopausal women.

Based on a lot of favorable publicity, health-conscious people are increasingly adding flax seed to their diet for the purpose of obtaining the beneficial lignans. Highly concentrated lignan extracts are also appearing in supplements to support breast and prostate health.

Adding Up the Numbers

According to the scientific data discussed in this article, significant reductions (up to 90%) in breast cancer risk have been found based on the types of foods and supplements one consumes.25

Even further risk reductions occur in conjunction with lowered overall calorie intake. In fact, for each excess calorie we ingest (and most of us ingest plenty of excess calories), our risk for many types of cancer increases.26,82,83

In adding up these numbers, it becomes clear that there are many steps one can take to sharply reduce the risk of breast, prostate, and other cancers. An evaluation of how certain plant extracts favorably affect estrogen metabolism indicates that aging humans may be able to safely benefit from natural hormone balancing.

Is Fear of Cancer a Reason to Be Deprived of Hormones?

As women enter the menopausal years, they face a difficult decision. The body’s natural production of estrogen, progesterone, DHEA, and other critical hormones needed to maintain health and vigor rapidly declines.84 While individual effects of menopause vary widely, most women suffer because their glands no longer produce the hormones needed to regulate critical physiological processes. Depression, irritability, and short-term memory lapses are common menopausal complaints, along with hot flashes, night sweats, and insomnia.85

Aging men suffer a host of disorders that range from unpleasant to lethal in response to testosterone deficiency and estrogen overload.86-92

Concern about cancer is the primary reason why men and women do not restore their hormones to more youthful levels. Like much of what we eat, estrogen and testosterone affect cell proliferation. Does that mean we should shrivel up, degenerate, and die from these sex hormone deficiencies we all face as a part of “normal” aging?

Based on the enormity of the data showing how people can sharply reduce their rate of cancer and favorably affect estrogen metabolism in a way that points to cancer prevention, it is difficult to buy into the argument that natural sex hormones should only be enjoyed by the young.

Large human population studies show huge reductions in cancer risk, along with specific protective mechanisms against estrogen’s negative pathways, when vitamin D, cruciferous vegetables (I3C), soy, D-glucarate, and lignans are consumed. Dramatic cancer rate reductions also occur when red meat, high-fat dairy, and other deleterious foods are reduced or eliminated from the diet.

Misconceptions generated by conflicting studies and media hype have created an environment in which aging people suffer the agonies and shortened life spans caused by sex hormone imbalances, yet do nothing to correct this due to fear of cancer. When one looks at what the real risk factors are, it would appear that altering one’s lifestyle at any age would result in significant cancer reductions, even in those who properly restore their hormone balance to reflect a more youthful range.

Remember the chart at the beginning of this article showing how breast cancer rates skyrocket as we age. During the younger years, when breast cancer is virtually non-existent, we enjoy high levels of youthful sex hormones (estrogen, progesterone, DHEA, and testosterone). As hormone levels decline with age, breast and prostate cancer risks increase. We now know this happens because of the “accumulation of mutations in our genes that regulate cellular proliferation.” 2 The incredible news is that there are low-cost nutrients that are proven to favorably restore healthy gene function and reduce our risk of cancer in the process.

Just think, we have been told all our lives that there is nothing we can do about the genes we inherit from our parents that predispose us to certain diseases. Yet breakthrough research findings indicate that we can influence our genes to behave in a way that significantly reduces our risk of contracting common cancers. Additional scientific findings show how we can influence estrogen metabolism in our bodies so that it is protective against breast and other cancers.

Based on the enormity of this data, it would appear that aging humans can restore many of the hormones they need to sustain life—without encountering adverse effects.

If you have any questions on the scientific content of this article, please call a Life Extension Health Advisor at 1-800-226-2370.

References

1. Irminger-Finger I. Science of cancer and aging. J Clin Oncol. 2007 May 10;25(14):1844-51.

2. Simone CB. Cancer and Nutrition. Lawrenceville, NJ: Princeton Institute; 2005.

3. Haber D. Roads leading to breast cancer. N Engl J Med. 2000 Nov 23;343(21):1566-8.

4. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet. 1989 Nov 18;2(8673):1176-8.

5. Garland CF, Garland FC, Gorham ED. Can colon cancer incidence and death rates be reduced with calcium and vitamin D? Am J Clin Nutr. 1991 Jul;54(1 Suppl):193S-201S.

6. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11.

7. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):179-94.

8. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. Cancer Res. 2005 Jun 15;65(12):5470-9.

9. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health. 2006 Feb;96(2):252-61.

10. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007 Jun;85(6):1586-91.

11. Friedrich M, Rafi L, Mitschele T, et al. Analysis of the vitamin D system in cervical carcinomas, breast cancer and ovarian cancer. Recent Results Cancer Res. 2003;164:239-46.

12. de Lyra EC, da S, I, Katayama ML, et al. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer. J Steroid Biochem Mol Biol. 2006 Aug;100(4-5):184-92.

13. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol. 2006 Sep;92(1):49-59.

14. Skinner HG, Michaud DS, Giovannucci E, et al. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1688-95.

15. Zhang X, Nicosia SV, Bai W. Vitamin D receptor is a novel drug target for ovarian cancer treatment. Curr Cancer Drug Targets. 2006 May;6(3):229-44.

16. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001 Jan;165(1):253-8.

17. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005 Jun;10(2):94-111.

18. Mernitz H, Smith DE, Wood RJ, Russell RM, Wang XD. Inhibition of lung carcinogenesis by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in the A/J mouse model: evidence of retinoid mitigation of vitamin D toxicity. Int J Cancer. 2007 Apr 1;120(7):1402-9.

19. Becker S, Cordes T, Diesing D, Diedrich K, Friedrich M. Expression of 25 hydroxyvitamin D3-1alpha-hydroxylase in human endometrial tissue. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):771-5.

20. Polesel J, Talamini R, Montella M, et al. Linoleic acid, vitamin D and other nutrient intakes in the risk of non-Hodgkin lymphoma: an Italian case-control study. Ann Oncol. 2006 Apr;17(4):713-8.

21. Imseis RE, Palmieri GM, Holbert JM, Leventhal MR, Sebes JI. Effect of calcitriol and pamidronate in multiple myeloma. Am J Med Sci. 1999 Jul;318(1):61-6.

22. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81.

23. Zhu G, Zhang YQ, Wan B. Role of dietary factors in prostate cancer development. Zhonghua Nan Ke Xue. 2005 May;11(5):375-8

24. Taylor EF, Burley VJ, Greenwood DC, Cade JE. Meat consumption and risk of breast cancer in the UK Women’s Cohort Study. Br J Cancer. 2007 Apr 10;96(7):1139-46.

25. Cui X, Dai Q, Tseng M et al. Dietary patterns and breast cancer risk in the shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1443-8.

26. Silvera SA, Jain M, Howe GR, Miller AB, Rohan TE. Energy balance and breast cancer risk: a prospective cohort study. Breast Cancer Res Treat. 2006 May;97(1):97-106.

27. Tavani A, Giordano L, Gallus S, et al. Consumption of sweet foods and breast cancer risk in Italy. Ann Oncol. 2006 Feb;17(2):341-5.

28. Lajous M, Willett W, Lazcano-Ponce E, et al. Glycemic load, glycemic index, and the risk of breast cancer among Mexican women. Cancer Causes Control. 2005 Dec;16(10):1165-9.

29. Moorman PG, Terry PD. Consumption of dairy products and the risk of breast cancer: a review of the literature. Am J Clin Nutr. 2004 Jul;80(1):5-14.

30. Brennan P, Hsu CC, Moullan N, et al. Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach. Lancet. 2005 Oct 29;366(9496):1558-60.

31. Ambrosone CB, McCann SE, Freudenheim JL, et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004 May;134(5):1134-8.

32. Kristal AR, Lampe JW. Brassica vegetables and prostate cancer risk: a review of the epidemiological evidence. Nutr Cancer. 2002;42(1):1-9.

33. Jin L, Qi M, Chen DZ, et al. Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res. 1999 Aug 15;59(16):3991-7.

34. Zhang SM, Hunter DJ, Rosner BA, et al. Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin’s lymphoma among women. Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):477-85.

35. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-7.

36. Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res. 2007 May;635(2-3):90-104.

37. Conaway CC, Wang CX, Pittman B, et al. Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. Cancer Res. 2005 Sep 15;65(18):8548-57.

38. Kall MA, Vang O, Clausen J. Effects of dietary broccoli on human drug metabolising activity. Cancer Lett. 1997 Mar 19;114(1-2):169-70.

39. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996 Sep;150 SupplS259-65.

40. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000 Nov;11(6):635-40.

41. Muti P, Westerlind K, Wu T, et al. Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control. 2002 Dec;13(10):947-55.

42. Yoo HJ, Sepkovic DW, Bradlow HL, Yu GP, Sirilian HV, Schantz SP. Estrogen metabolism as a risk factor for head and neck cancer. Otolaryngol Head Neck Surg. 2001 Mar;124(3):241-7.

43. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):505-9.

44. Kabat GC, O’Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology. 2006 Jan;17(1):80-8.

45. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):773-9.

46. Fowke JH, Qi D, Bradlow HL, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids. 2003 Jan;68(1):65-72.

47. Michnovicz JJ, Adlercreutz H, Bradlow HL. Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997 May 21;89(10):718-23.

48. Wong GY, Bradlow L, Sepkovic D, et al. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J Cell Biochem Suppl. 1997;28-29:111-6.

49. Hirose K, Tajima K, Hamajima N, et al. A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res. 1995 Feb;86(2):146-54.

50. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998 Dec;9(6):553-7.

51. Kurahashi N, Iwasaki M, Sasazuki S, et al. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45.

52. Messina MJ. Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr. 1999 Sep;70(3 Suppl):439S-50S.

53. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-913.

54. Lee MM, Gomez SL, Chang JS, et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8.

55. Schabath MB, Hernandez LM, Wu X, Pillow PC, Spitz MR. Dietary phytoestrogens and lung cancer risk. JAMA. 2005 Sep 28;294(12):1493-504.

56. Nothlings U, Murphy SP, Wilkens LR, Henderson BE, Kolonel LN. Flavonols and Pancreatic Cancer Risk: The Multiethnic Cohort Study. Am J Epidemiol. 2007 Aug 9.

57. Xu HS, Dai SL, Sun RY. Cardiovascular effects of phytoestrogens. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Apr;27(2):258-61.

58. de Kleijn MJ, van der Schouw YT, Wilson PW, Grobbee DE, Jacques PF. Dietary intake of phytoestrogens is associated with a favorable metabolic cardiovascular risk profile in postmenopausal U.S.women: the Framingham study. J Nutr. 2002 Feb;132(2):276-82.

59. Roudsari AH, Tahbaz F, Hossein-Nezhad A, et al. Assessment of soy phytoestrogens’ effects on bone turnover indicators in menopausal women with osteopenia in Iran: a before and after clinical trial. Nutr J. 2005;430.

60. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S. Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13.

61. Barnes S. Effect of genistein on in vitro and in vivo models of cancer. J Nutr. 1995 Mar;125(3 Suppl):777S-83S.

62. Setchell KD. Soy isoflavones—benefits and risks from nature’s selective estrogen receptor modulators (SERMs). J Am Coll Nutr. 2001 Oct;20(5 Suppl):354S-62S; discussion 381S-383S.

63. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast-cancer risk in Singapore. Lancet. 1991 May 18;337(8751):1197-200.

64. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64.

65. Schroder FH, Roobol MJ, Boeve ER, et al. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. Eur Urol. 2005 Dec;48(6):922-30.

66. Nagata Y, Sonoda T, Mori M, et al. Fujimoto Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007 Aug;137(8):1974-9.

67. Available at: http://www.cdc.gov/omhd/Highlights/2007/HJune07.htm#2. Accessed August 10. 2007.

68. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 2004 Mar;95(3):238-42.

69. Ozasa K, Nakao M, Watanabe Y, et al. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 2004 Jan;95(1):65-71.

70. Available at: http://www.garfield.library.upenn.edu/histcomp/kritchevsky-d_auth-citing/node/7082.html. Accessed August 20, 2007.

71. Dwivedi C, Heck WJ, Downie AA, Larroya S, Webb TE. Effect of calcium glucarate on beta-glucuronidase activity and glucarate content of certain vegetables and fruits. Biochem Med Metab Biol. 1990 Apr;43(2):83-92.

72. Walaszek Z, Szemraj J, Narog M et al. Metabolism, uptake, and excretion of a D-glucaric acid salt and its potential use in cancer prevention. Cancer Detect Prev. 1997;21(2):178-90.

73. No authors listed. Calcium-D-glucarate. Altern Med Rev. 2002 Aug;7(4):336-9.

74. Walaszek Z, Hanausek M, Sherman U, Adams AK. Antiproliferative effect of dietary glucarate on the Sprague-Dawley rat mammary gland. Cancer Lett. 1990 Jan;49(1):51-7.

75. Heerdt AS, Young CW, Borgen PI. Calcium glucarate as a chemopreventive agent in breast cancer. Isr J Med Sci. 1995 Feb;31(2-3):101-5.

76. Slaga TJ, Quilici-Timmcke J. D-Glucarate: A Nutrient Against Cancer. Columbus, Ohio: McGraw-Hill; 1999.

77. Walaszek Z, Hanausek-Walaszek M, Minton JP, Webb TE. Dietary glucarate as anti-promoter of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis. Carcinogenesis. 1986 Sep;7(9):1463-6.

78. Abou-Issa H, Moeschberger M, el-Masry W, et al. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res. 1995 May;15(3):805-10.

79. Magnúsdóttir EV. Phytoestrogens and human health. Laeknabladid. 2002 Nov;88(11):821-5.

80. McCann SE, Muti P, Vito D, et al. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int J Cancer. 2004 Sep 1;111(3):440-3.

81. Boccardo F, Lunardi G, Guglielmini P, et al. Serum enterolactone levels and the risk of breast cancer in women with palpable cysts. Eur J Cancer. 2004 Jan;40(1):84-9.

82. Slattery ML, Potter J, Caan B, et al. Energy balance and colon cancer--beyond physical activity. Cancer Res. 1997 Jan 1;57(1):75-80.

83. Michels KB. The role of nutrition in cancer development and prevention. Int J Cancer. 2005 Mar 20;114(2):163-5.

84. Freeman EW, Sammel MD, Lin H, et al. Symptoms associated with menopausal transition and reproductive hormones in midlife women. Obstet Gynecol. 2007 Aug;110(2 Pt 1):230-40.

85. Von Bamberger CM. Prevention and anti-aging in endocrinology. MMW Fortschr Med. 2007 Mar 1;149(9):33-5.

86. Izumi S, Tsubahara A. Improvement of peripheral neuropathy by testosterone in a patient with 48,XXYY syndrome. Tokai J Exp Clin Med. 2000 Jun;25(2):39-44.

87. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994 May;14(5):701-6.

88. Hak AE, Witteman JC, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9.

89. Pope HG, Jr., Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003 Jan;160(1):105-11.

90. Zumoff B. Hormonal abnormalities in obesity. Acta Med Scand Suppl. 1988;723:153-60.

91. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male. 2002 Jun;5(2):98-102.

92. Novák A, Brod M, Elbers J. Andropause and quality of life: findings from patient focus groups and clinical experts. Maturitas. 2002 Dec 10;43(4):231-7.

93. Bradlow HL, Sepkovic DW, Telang NT, Osborne MP. Indole-3-carbinol. A novel approach to breast cancer prevention. Ann N Y Acad Sci. 1995 Sep 30;768:180-200.

94. Zumoff B. Hormonal profiles in women with breast cancer. Obstet Gynecol Clin North Am. 1994 Dec;21(4):751-72.

95. Napoli N, Armamento-Villareal R. Estrogen hydroxylation in osteoporosis. Adv Clin Chem. 2007;43:211-27.

96. Bradlow HL, Telang NT, Sepkovic DW, Osborne MP. 2-hydroxyestrone: the ‘good’ estrogen. J Endocrinol. 1996 Sep;150 Suppl:S259-65.